Core Insights - Norwegian Cruise Line Holdings Ltd. has appointed Marc Kazlauskas as President of Norwegian Cruise Line, effective January 19, 2026, bringing over 30 years of experience in the global travel industry [1][2][3] Company Overview - Norwegian Cruise Line Holdings operates Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises, with a combined fleet of 34 ships and over 71,000 berths, offering itineraries to approximately 700 destinations worldwide [4] - The company plans to add 14 additional ships across its brands by 2036, which will increase its fleet capacity by over 39,200 berths [4] Leadership Background - Marc Kazlauskas previously served as CEO of Avoya Travel and held leadership roles at FROSCH and Chase Travel Group, managing operations with over $11 billion in sales [2] - He has a proven track record in enhancing customer experience and driving commercial performance, aligning with Norwegian's focus on operational efficiency and guest offerings [2][3] Strategic Initiatives - The appointment of Kazlauskas comes at a crucial time for Norwegian Cruise Line, as the company is experiencing healthy demand for cruises and is executing its newbuild program [3] - Key initiatives include enhancements to Great Stirrup Cay, Norwegian's private island in the Bahamas, and the upcoming debut of Norwegian Luna [3] Market Positioning - Norwegian Cruise Line is recognized for its innovative approach to cruising, offering guests flexibility in vacation planning and a variety of curated experiences [5] - The company provides a signature Free at Sea™ package, which includes benefits such as unlimited open bar, specialty dining credits, and shore excursion credits [5]

Proposals of the Shareholders’ Nomination Board of Siili Solutions Plc to the AGM 2026 Siili Solutions Plc Stock Exchange Release 11 December 2025 at 16:00 EET The Annual General Meeting of Siili Solutions Plc is planned to be held on 8 April 2026. The Shareholders’ Nomination Board of Siili Solutions Plc proposes to the Annual General Meeting that the AGM decide on the composition and remuneration of the Company’s Board of Directors as follows: Decision on the number of members of the Board of DirectorsThe ...

Core Points - Q2 Metals Corp. announced that all matters at the Annual General Meeting held on December 9, 2025, were approved, with 73,179,989 common shares represented, accounting for 38.62% of the outstanding shares as of October 24, 2025 [1] - A live year-end webcast presentation is scheduled for December 18, 2025, where management will review the company's 2025 performance and outline plans for 2026 [2] - Q2 Metals is focused on the Cisco Lithium Project located in Quebec, Canada, which is strategically positioned near infrastructure [3] Exploration Potential - The Cisco Project has an initial Exploration Target estimating lithium mineralization between 215 to 329 million tonnes at grades of 1.0 to 1.38% Li2O, based on the first 40 drilled holes [4] - The ongoing 2025 Exploration Program prioritizes infill drilling, with an initial mineral resource estimate expected in Q1 2026, while expansion drilling continues at high-potential targets across the 41,253-hectare project area [5]

Fluence among top three providers worldwide based on installed and contracted capacityARLINGTON, Va., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (“Fluence”) (NASDAQ: FLNC), a global market leader delivering intelligent energy storage systems, services, and asset optimization software, has been recognized as one of the top three battery energy storage system providers worldwide in the newly released S&P Global Commodity Insights 2025 Battery Energy Storage System Integrator Report. The independen ...

Core Insights - MAIA Biotechnology has initiated the first patient dosing in the THIO-104 Phase 3 pivotal trial for ateganosine, a treatment for advanced non-small cell lung cancer (NSCLC) [1][3] - The trial aims to compare the overall survival of ateganosine sequenced with a checkpoint inhibitor against chemotherapy in patients resistant to previous treatments [2][6] - The FDA has granted Fast Track designation for ateganosine, indicating its potential significance in treating NSCLC [4] Company Overview - MAIA Biotechnology is focused on developing targeted immunotherapies for cancer, with ateganosine as its lead program targeting telomeres in cancer cells [5][8] - The company aims to improve survival rates for NSCLC patients, with Phase 2 data showing a median survival of 17.8 months for ateganosine compared to approximately six months for chemotherapy [3][5] Clinical Trial Details - The THIO-104 trial is a multicenter, open-label study designed to enroll up to 300 patients, assessing the efficacy and safety of ateganosine in combination with a checkpoint inhibitor [2][6] - The primary endpoint of the trial is median overall survival, with safety and tolerability also being evaluated [6]

AUO received global leadership recognition with a Double “A” rating from CDP for Climate Change and Water Security AUO received global leadership recognition with a Double “A” rating from CDP for Climate Change and Water Security. In 2023, AUO’s headquarters GRC Building became the first in Taiwan to achieve ISO 14068 Carbon Neutral Verification, setting a pioneering industry benchmark. HSINCHU, Taiwan, Dec. 11, 2025 (GLOBE NEWSWIRE) -- As extreme weather and water security increasingly impact global cl ...

HONG KONG, Dec. 11, 2025 (GLOBE NEWSWIRE) -- As Christmas 2025 approaches, finding a perfect gift for loved ones can be challenging. To make the choice easier, Oukitel presents five top-tier devices sure to impress every recipient. Featuring the world’s first 7.2" display, a massive 33,000mAh battery with an integrated projector, and a versatile dual-screen design, these gadgets combine cutting-edge performance with groundbreaking innovation, delivering an exceptional technology experience. Powered by all t ...

Core Insights - Inotiv, Inc. has announced a strategic collaboration with VUGENE to enhance AI-assisted drug discovery and improve data-driven insights across the drug development continuum [1][2]. Company Overview - Inotiv, Inc. is a leading Contract Research Organization (CRO) that specializes in nonclinical and analytical drug discovery and development services, as well as research models and related products [1][4]. - The company focuses on increasing efficiency, improving data quality, and reducing costs associated with bringing new drugs and medical devices to market [4]. Collaboration Details - The partnership will integrate VUGENE's cloud-based bioinformatics and computational platform into Inotiv's Discovery & Translational Sciences Division, facilitating more efficient analysis of complex biological data [2][3]. - This collaboration aims to enhance Inotiv's capabilities in interpreting various molecular datasets, ultimately improving predictions of drug efficacy and safety during early-stage research [2][3]. Strategic Goals - The collaboration is expected to enable clients to make faster and more informed decisions by leveraging VUGENE's AI-enabled bioinformatics platform [3]. - The partnership represents an opportunity for VUGENE to expand the application of its computational technologies in real-world research environments [3][5]. Technological Integration - VUGENE's platform integrates biological data from multiple sources, including (epi)genomics, transcriptomics, proteomics, and metabolomics, to elucidate disease mechanisms and therapeutic modes of action [5].

GRAND CAYMAN, Cayman Islands, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Oxbridge Re Holdings Limited (NASDAQ: OXBR), (the “Company”), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary SurancePlus, today announced a strategic partnership with Alphaledger, a leading developer of RWA (Real World Assets) Solana-native tokenized securities infrastructure. The partnership, formally unveiled at Solana Breakpoint 2025, marks SurancePlus’ first official entry i ...

Core Insights - Verizon Business has upgraded Empower Field at Mile High to a Wi-Fi 6E-ready network, enhancing the game-day experience for fans and improving stadium operations [1][4]. Group 1: Network Upgrade Details - The new network installation includes over 2,400 wireless access points, providing fast and reliable internet access for fans and operational teams [1][3]. - The legacy Wi-Fi network has been completely replaced with a best-in-class network that utilizes a dedicated 6GHz frequency band, facilitating easier management and scalability [4]. - The deployment incorporates WPA3 security standards, ensuring stronger encryption and protection of sensitive operational data [4]. Group 2: Operational Enhancements - The upgraded network supports various operational functions, including POS systems, surveillance, crowd management, digital ticketing, and access control, ensuring seamless operations [3][5]. - Verizon has also installed 965 antennas to enhance 5G coverage throughout the stadium, allowing fans to access 5G services in all areas, including tailgating zones [5]. Group 3: Strategic Vision - Verizon's Connected Venues approach combines public and private network capabilities with advanced technologies to redefine sports and venue operations [6]. - The collaboration with the Denver Broncos represents a significant investment in technology aimed at delivering exceptional fan experiences year-round [2][5]. Group 4: Company Overview - Verizon Communications Inc. generated revenues of $134.0 billion in 2023 and continues to innovate to meet customer demands for mobility and reliable connectivity [7].